Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2021-10-05 Regulatory Filings
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The content focuses on a change in the audit committee membership and compliance with Nasdaq listing rules, specifically the resignation of a member and appointment of a new member to the audit committee. There is no financial data or detailed financial performance information. The document is not an annual or quarterly report, earnings release, or any other detailed financial report. It is a regulatory announcement about board committee changes and compliance with listing standards. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-10-05 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 29, 2021, by Protagenic Therapeutics, Inc. It reports the results of the 2021 Annual Meeting of Stockholders, including voting results on director elections and an amendment to the Certificate of Incorporation to classify the board into three classes. It also includes the ratification of the independent auditor. The document contains detailed voting results and the filing of the Classified Board Amendment. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an Annual Report, Audit Report, or Management Report, but specifically reports shareholder voting outcomes. The length (6424 characters) and content confirm it is not a brief announcement but a full voting results report. Therefore, the correct classification is DVA with high confidence.
2021-10-01 English
Regulatory Filings 2021
Regulatory Filings
2021-09-20 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Protagenic Therapeutics, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3/A. It references a filing (Form S-3/A) but does not contain financial data or the registration statement itself. The document length is short (1169 characters) and is a formal request related to a filing process, not a report or financial statement. This fits the category of a Regulatory Filing (RNS), which covers miscellaneous regulatory communications that do not fit other categories.
2021-09-15 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a pre-effective amendment to a Registration Statement on Form S-3 filed with the SEC. It includes detailed information about the securities being registered, the selling stockholders, and the terms of the offering. The Form S-3 is a registration statement used for securities offerings, not a financial report or earnings release. The document is lengthy (15,000 characters) and contains the full registration statement text, not just an announcement or a brief notice. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-09-10 English
Proxy Solicitation & Information Statement 2021
Proxy Solicitation & Information Statement
2021-09-08 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.